Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Randomized, Open-Label Comparison of Lopinavir/Ritonavir Plus Efavirenz Versus Lopinavir/Ritonavir Plus 2 NRTIs Versus Efavirenz Plus 2 NRTIs as Initial Therapy for HIV-1 Infection.

Trial Profile

A Phase III, Randomized, Open-Label Comparison of Lopinavir/Ritonavir Plus Efavirenz Versus Lopinavir/Ritonavir Plus 2 NRTIs Versus Efavirenz Plus 2 NRTIs as Initial Therapy for HIV-1 Infection.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 02 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Efavirenz (Primary) ; Lamivudine (Primary) ; Lopinavir/ritonavir (Primary) ; Nucleoside reverse transcriptase inhibitors (Primary) ; Stavudine (Primary) ; Tenofovir disoproxil fumarate (Primary) ; Zidovudine (Primary)
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Aug 2020 Results (n=757) of a retrospective, observational cohort of individuals receiving primary care at the vanderbilt comprehensive care clinic and a retrospective analysis of a clinical trials (A5095, A5142 and A5202 and did not receive INSTIs) cohort from efavirenz containing arms of ACTG protocols has been published in the Clinical Infectious Diseases.
    • 01 Sep 2017 Results assessing the association between efavirenz metabolizer genotype and suicidality using pooled data from four clinical trials (A5095, A5142 ,A5175, A5202), published in the Journal of Infectious Diseases.
    • 16 Feb 2017 Results of pooled analysis of 3 ACTG U.S based randomized trials (A5142, A5202 and A5257) presented at the 24th Conference on Retroviruses and Opportunistic Infections
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top